Regencell Bioscience Holdings (RGC) Fundamentals 2026 — Revenue Analysis | SniperIQ
Regencell Bioscience Holdings (RGC) is a HK-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Regencell Bioscience Holdings (RGC) has a market capitalization of approximately
Regencell Bioscience Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2449.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Regencell Bioscience Holdings runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Regencell Bioscience Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Regencell Bioscience Holdings carries a debt-to-equity ratio of 0.32x and a current ratio of 1.42x, with a market beta of 1.83. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Regencell Bioscience Holdings (RGC) the key facts are: market cap
Get Regencell Bioscience Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.